<DOC>
	<DOCNO>NCT00885794</DOCNO>
	<brief_summary>Diabetic maculopathy lead cause visual impairment working-age population develop country . Diabetic macular edema cause impair visual acuity far treat laser , vitreous surgery , intravitreal cortisone application . Still 50 % case respond treatment . Recently intraocular anti-VEGF-treatment ranibizumab ( Lucentis® , Novartis ) diabetic macular edema proven efficacy last period 3 6 month . Still , optimal dosage intravitreal injection still find , frequent injection necessary . The measurement visual acuity inadequate quantify detail visual impairment . Using new technology high-definition optical coherence tomography ( Cirrus-OCT , Carl Zeiss Meditec Inc. ) determine retinal thickness , miroperimetry ( MP-1 , Nidek Technologies ) determine retinal sensitivity , hope find optimal dosage intravitreal anti-VEGF treatment diabetic macular edema . Study objective : To determine dose response 0.5mg 1.0mg ranibizumab ( Lucentis® , Novartis Pharma ) intravitreal injection subject resistant diabetic macular edema evaluate safety tolerability .</brief_summary>
	<brief_title>Microperimetry Optical Coherence Tomography ( OCT ) With Lucentis Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description>Diabetic maculopathy due diabetic macular edema ( DME ) lead cause visual impairment working-age population develop country . DME swell retina result exudation accumulation extracellular fluid protein macula . Structural change endothelium retinal vessel lead breakdown blood-retina barrier increase vascular permeability , result exudation . The standardized treatment DME focal laser GRID-laser treatment without combine triamcinolone intravitreal injection . Those laser treatment produce scars central retina always effective . In case macular traction taut posterior hyloid vitrectomy retinal surgery necessary . Vascular endothelial growth factor ( VEGF ) implicate important factor occurrence vascular permeability DME . In patient DME , VEGF level significantly elevate , compare patient without ocular disease . Therefore , anti-VEGF treatment implicate important treatment DME recently intraocular anti-VEGF-treatment ranibizumab ( Lucentis® , Novartis Pharma ) diabetic macular edema proven effective . Just like patient age-related macular degeneration ( AMD ) , anti-VEGF treatment give 3 time every 4-6 week . The treatment repeat relapse disease , 3 time every 4-6 week . One study group treat DME 0.5mg ranibizumab intravitreal injection compare 0.3mg 0.5mg ranibizumab intravitreal injection . An optimal treatment dose find yet . Visual acuity assessment currently use determine functional damage cause edema , although may completely describe functional condition patient . Furthermore , visual acuity alone seem best parameter define effect continuation treatment . Retinal thickness , measure noninvasive optical coherence tomography ( OCT ) deliver detailed information retinal situation treatment . Also fundus related perimetry , know microperimetry ( MP ) , useful noninvasive examination method determine site relative absolute scotoma also fixation characteristic . With MP macular sensitivity measure assess macular condition . Using new technology high-definition OCT ( Cirrus-OCT , Carl Zeiss Meditec Inc. ) determine retinal thickness , MP automate correction eye movement ( MP-1 , Nidek Technologies ) determine retinal sensitivity , intend analyze new treatment option DME , find optimized dose intravitreal injection ranibizumab case ineffective laser treatment .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Study eye clinically significant macular edema , one follow characteristic present : retinal thickening within 500µm center macula , hard exudate within 500µm center macula associate thicken adjacent retina , zone ( &gt; 1disk area ) zone retinal thicken part within 1 disk diameter center macula . Second line treatment ineffective laser treatment Men woman diabetes mellitus Only one eye per patient Age &gt; 50 year HbA1c &lt; 8 % Study eye concomitant retinal choroidal disorder diabetic retinopathy Study eye significant central lens opacity / condition limit view fundus poor general condition woman childbearing potential , current pregnancy breastfeeding Patients unwilling adhere visit examination schedule Evidence macular traction taut posterior hyloid .</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Clinically Significant Diabetic Macular Edema</keyword>
	<keyword>Focal Laser</keyword>
	<keyword>GRID-Laser</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Microperimetry</keyword>
	<keyword>High-Definition OCT</keyword>
	<keyword>Randomized</keyword>
	<keyword>Observer-Blinded</keyword>
	<keyword>Ineffective Treatment Focal Laser GRID-Laser</keyword>
</DOC>